QuidelOrtho Secures $1.15 Billion Refinancing to Enhance Growth and Financial Flexibility

QuidelOrtho Secures Strategic Refinancing to Propel Growth

QuidelOrtho Corporation, a leader in in-vitro diagnostic technologies, undertakes significant refinancing to bolster its financial foundation and enhance growth prospects. The company successfully secures a $1.15 billion 5-year senior secured Term Loan A, which replaces an earlier loan initiated in 2022, along with a $100 million delayed draw Term Loan A that remains undrawn at closing. This strategic refinancing also includes a $1.45 billion 7-year senior secured Term Loan B and a $700 million revolving credit facility, effectively paying off the prior credit facility. CFO Joseph Busky expresses satisfaction with these developments, highlighting their role in strengthening the capital structure and improving cash flow.

The refinancing initiative significantly impacts QuidelOrtho's capital allocation strategy. Busky indicates that the primary focus will now shift towards reducing total debt and net debt leverage. This restructuring not only enhances the terms of the debt covenants but also lowers amortization requirements throughout the loan's duration, providing the company with increased financial flexibility. The new arrangements position QuidelOrtho to better respond to future growth opportunities while ensuring a more manageable debt burden.

QuidelOrtho remains committed to advancing its innovative diagnostic solutions, which are designed to deliver rapid and reliable testing across multiple healthcare settings, including home, hospital, lab, and clinic environments. The company’s ongoing efforts to integrate insights seamlessly into its testing solutions facilitate informed healthcare decisions, reinforcing its mission to power a healthier future. As QuidelOrtho collaborates with global healthcare partners, it further solidifies its role as a key player in the diagnostic technology sector, poised for continued growth and innovation.

In addition to its refinancing activities, QuidelOrtho files a Form 8-K with the Securities and Exchange Commission to detail the terms of these transactions. This transparency underscores the company's commitment to maintaining open communication with stakeholders, ensuring they remain informed about significant financial developments. For more information about QuidelOrtho's innovative diagnostic solutions and corporate strategies, interested parties can visit quidelortho.com or connect with the company through its social media channels.